SCHEMBL19793476

SCHEMBL19793476

C=CCCc1cc2ccc(OCC)c(F)c2c(=O)o1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.34
CA9 Q16790 5/20 0.33
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 3/20 0.32
FGFR2 P21802 1/20 0.31
CA12 O43570 2/20 0.31
CA1 P00915 2/20 0.31
ADORA3 P0DMS8 2/20 0.31
CA2 P00918 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
MAPT P10636 2/20 0.31
CYP1A2 P05177 1/20 0.31
CA4 P22748 1/20 0.31
CA6 P23280 1/20 0.31
CA5A P35218 1/20 0.31
CA7 P43166 1/20 0.31
CA14 Q9ULX7 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
SRD5A1 P18405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19793478 0.93 ELANE (0.32) ELANECA9KDM4EALDH1A1
SCHEMBL19793481 0.91 CA9 (0.36) CA9KDM4EALDH1A1CA12CA1
SCHEMBL19793485 0.90 CA9 (0.37) CA9KDM4EALDH1A1CA12CA1
SCHEMBL19793567 0.89 CA12 (0.37) CA9KDM4EALDH1A1CA12CA1
SCHEMBL19793580 0.89 KDM4E (0.33) KDM4E
SCHEMBL19793488 0.89 MAPT (0.38) ELANECA9KDM4EALDH1A1CA12
SCHEMBL19793471 0.88 KDM4E (0.39) ELANECA9KDM4EALDH1A1MAPT
SCHEMBL19793474 0.88 KDM4E (0.36) ELANECA9KDM4EALDH1A1FGFR2
SCHEMBL19793493 0.88 MAPT (0.40) ELANECA9MAPT
SCHEMBL19793500 0.88 MAPT (0.40) ELANECA9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10428273-B2 Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2019-10-01 US disclosed
US-20180022998-A1 LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-01-25 US disclosed
US-20180022998-A1 LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428273-B2 Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device PIEZO1, PYCARD, NLRP1 ELANE 2653/4885CA9 1337/4885KDM4E 2394/4885
US-20180022998-A1 LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE PIEZO1, NLRP1, PYCARD ELANE 2588/4885CA9 1366/4885KDM4E 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.